Accurius Therapeutics

Executive Summary

Accurius Therapeutics is a private, early-stage biotechnology company headquartered in Cambridge, MA, focused on developing novel oncolytic immunotherapies for metastatic non-small cell lung cancer (NSCLC). Founded in 2021, the company integrates innovative oncolytic virus technology with advanced drug delivery systems to enhance tumor targeting, immune activation, and therapeutic efficacy. By leveraging cutting-edge delivery platforms, Accurius aims to overcome key limitations of current oncolytic therapies, such as poor intratumoral distribution and systemic immune suppression. The company's lead candidate is designed to selectively replicate in tumor cells, stimulate robust anti-tumor immune responses, and potentially improve outcomes for patients with advanced NSCLC. With a team of experienced researchers and commercial leaders, Accurius is positioned to advance its preclinical programs toward clinical development. Given the unmet need in metastatic NSCLC and the potential of oncolytic immunotherapy, the company represents an intriguing opportunity in the biotech landscape, though it remains at an early stage with no disclosed pipeline or financial details.

Upcoming Catalysts (preview)

• TBDIND/CTA Filing for Lead Oncolytic Program30% success
• TBDPreclinical Efficacy Data Presentation at Major Conference50% success
• TBDStrategic Partnership or Licensing Deal for Drug Delivery Platform25% success